School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

CYTOKINETICS INC CYTK

Healthcare · Biotechnology

$62.91last close 2026-10-09 · market cap $8.75B · delayed data

Trailing returns

1M-15.11%
3M-26.91%
6M-2.60%
1Y+4.31%
5Y+65.51%

Basis: Adjusted daily closes.

What it does

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Open CYTK in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies